Back to top
more

Stereotaxis (STXS)

(Delayed Data from AMEX)

$2.22 USD

2.22
521,720

-0.05 (-2.20%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Teleflex (TFX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Teleflex (TFX) delivered earnings and revenue surprises of +11.01% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial

by Zacks Equity Research

STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of 0% and 6.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of -100% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.98% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Sridatri Sarkar headshot

3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025

by Sridatri Sarkar

Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.

Urmimala Biswas headshot

Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?

by Urmimala Biswas

The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.

Zacks Equity Research

Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission

by Zacks Equity Research

STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.

Zacks Equity Research

STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval

by Zacks Equity Research

Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of -80% and 9.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TransMedics (TMDX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 5.56% and 10.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

STXS Stock Gains Following the First Order for its GenesisX

by Zacks Equity Research

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.

Zacks Equity Research

STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot

by Zacks Equity Research

Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.

Zacks Equity Research

STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System

by Zacks Equity Research

Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of -60% and 35.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Delcath Systems, Inc. (DCTH) Reports Q3 Loss

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of 76.92% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of 10.34% and 3.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX

by Zacks Equity Research

Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.

Zacks Equity Research

Stereotaxis (STXS) Receives European Approval for GenesisX

by Zacks Equity Research

Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of -75% and 21.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo (MASI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 11.69% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 15.38% and 2.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis (STXS) Gets CE Recertification for Approved Products

by Zacks Equity Research

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.